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VAMP1 Mutation Causes Dominant
Hereditary Spastic Ataxia in Newfoundland Families
Cynthia V. Bourassa,1,2 Inge A. Meijer,1,2 Nancy D. Merner,1,2 Kanwal K. Grewal,3 Mark G. Stefanelli,3
Kathleen Hodgkinson,4 Elizabeth J. Ives,3 William Pryse-Phillips,5 Mandar Jog,6 Kym Boycott,7
David A. Grimes,8 Sharan Goobie,9 Richard Leckey,10 Patrick A. Dion,1,2 and Guy A. Rouleau1,2,11,*
Our group previously described and mapped to chromosomal region 12p13 a form of dominantly inherited hereditary spastic ataxia
(HSA) in three large Newfoundland (Canada) families. This report identifies vesicle-associated membrane protein 1 (VAMP1), which
encodes a critical protein for synaptic exocytosis, as the responsible gene. In total, 50 affected individuals from these families and three
independent probands from Ontario (Canada) share the disease phenotype together with a disruptive VAMP1 mutation that affects
a critical donor site for the splicing of VAMP1 isoforms. This mutation leads to the loss of the only VAMP1 isoform (VAMP1A) expressed
in the nervous system, thus highlighting an association between the well-studied VAMP1 and a neurological disorder. Given the variable
phenotype seen in the affected individuals examined here, we believe that VAMP1 should be tested for mutations in patients with either
ataxia or spastic paraplegia.Spastic ataxia 1 (SPAX1 [MIM 108600]) is a rare neurode-
generative disorder characterized by lower-limb spasticity
and ataxia in the form of head jerks, ocular movement
abnormalities, dysphagia, dysarthria, and gait distur-
bance1,2 starting at the age of 10–20 years. Other clinical
features are supranuclear gaze palsy, hyperreflexia, hyper-
tonicity, dystonia, pes cavus, mild ptosis, and decreased
vibration sense in the lower limbs. Symptom severity
varies between individuals, but neither life span nor cogni-
tion is affected.1,2 This disease resembles both spinocere-
bellar ataxias (SCAs [MIM 164400]) and hereditary spastic
paraplegias (HSPs [MIM 182600]) but is part of a distinct
group: hereditary spastic ataxias (HSAs). Previous reports
describing the three Newfoundland (Canada) families
affected by SPAX1 had indicated the existence of an ances-
trally shared haplotype located in chromosomal region
12p13.1,2
A single neurologist (M.G.S.) diagnosed most of the
family members (Figures S2, S3, and S4A, available online),
and blood was collected for DNA analyses. More recently,
Dr. Jog ascertained an additional family (Figure S4B)
(with a Newfoundland origin [Figure S1]), and other
neurologists (K.B., D.A.G., and S.G.) identified three single
Ontario cases, all of whom presented with a similar SPAX1
phenotype. The collection of samples and genetic studies
were approved by the relevant ethic committees, and
informed consent was obtained from all subjects.
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Figure S3) and an unaffected control, was established. All
coding exons and flanking intron regions of the 53 genes
and predicted genes located in the 1.9 Mb disease haplo-
type were amplified by PCR. The PCR conditions and
primer sets are available upon request. PCR products
were sequenced at the McGill University and Ge´nome
Que´bec Innovation Centre (Montre´al, Canada), and the
sequences were analyzed with Mutation Surveyor v.3.0
(SoftGenetics). We searched for rare variants (those with
less than 1% allele frequency) that were exclusively present
in the two affected individuals of the mutation screening
panel. Variants that were previously reported in dbSNP
were excluded from further analysis. We determined the
allele frequency of the remaining interesting variants by
screening 169 Newfoundland population controls who
were previously collected for a regional colorectal cancer
study.3
A single variant of interest was observed in vesicle-asso-
ciatedmembrane protein 1 (VAMP1 [MIM 185880]) at posi-
tion chr12: g.6574054T>G (Figure 1A). VAMP1 has three
annotated isoforms, VAMP1A (RefSeq accession number
NM_014231.3), VAMP1B (RefSeq NM_016830.2), and
VAMP1D (RefSeq NM_199245.1), that only differ by their
last exon (Figure 1B). The primers amplifying VAMP1 are
given in Table S1. The mutation in VAMP1A and VAMP1B
is c.340þ2T>G, and the VAMP1D mutation is c.342T>G
(p.Ser114Arg). In order to predict the impact of the vari-
ants, we used in silico programs (SIFT,4 PolyPhen,5 andersite´ de Montre´al Research Center, Universite´ de Montre´al, Montre´al,
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Figure 1. VAMP1, from the Gene to Its
Encoded Protein
(A) A chromatogram of the variant chr12:
g.6574054T>G from an affected indi-
vidual is compared to that from a control.
(B) Representation of the three annotated
VAMP1 isoforms. The wider boxes are
exons, the medium boxes are UTRs, and
the lines are introns. The variant position
and the insert localization are indicated.
(C) A zoomed-in view of the variant re-
gion, including the amino acid sequences
of the annotated isoforms and themutated
sequence caused by the variant.PANTHER6) to predict pathogenicity on protein structure
and function and potential effect on RNA splicing
(BDGP7 and ESEfinder8). The p.Ser114Arg alteration is pre-
dicted to be damaging to the protein. The c.340þ2T>G
variant would disrupt mRNA splicing because it changes
the GT splicing donor site to GG in both VAMP1A and
VAMP1B.
Segregation of this particular variant was tested with
genomic DNA from every participant, and the variant
segregated with the disease in all four families, as well as
in the three single cases from Ontario. The presence of
this nucleotide mutation was also assessed in different
populations with the use of three databases: 1000
Genomes (see Web Resources), the National Heart, Lung,
and Blood Institute (NHLBI) Exome Variant Server (see
Web Resources), and our in-house exome database
composed of 708 individuals. In total, over 10,000 individ-
uals from Newfoundland and various unrelated popula-
tions were looked at; none of them has the chr12:
g.6574054T>G variant. Table 1 summarizes the genetic
results of the 110 study participants, and each pedigree
contains the information for each individual (Figures
S2–S4). At the functional level, we used lymphoblastoid
cell lines derived from patients in RT-PCR and immunoblot
experiments to confirm the impact of the identified muta-
tion at the RNA and protein levels. The expression of
VAMP1 in these cells was, however, too low for either of
these approaches to be informative, and unfortunately,
no biopsy or autopsy material was available for conducting
expression studies.The American Journal of Human GenThe mutation’s impact on normal
splicing was therefore assessed with
two VAMP1 minigenes (wild-type
and mutant alleles) that were ampli-
fied from a patient’s genomic DNA
(V-3 in Figure S2); the two minigenes
spanned from introns 3 to 4 (Fig-
ure 1B). Primer sequences and con-
ditions are shown in Table S2. PCR
products were separately inserted
into pENTR/D-TOPO (Invitrogen)
and transformed in One Shot TOP10competent E. Coli (Invitrogen). The recombination reac-
tions in pSPL3B_RFA, amodified pSPL3 vector (Invitrogen),
were performed with Gateway LR Clonase II (Invitrogen).
The cloning site of this vector is flanked by two constitutive
exons from the rabbit beta-globin gene (RefSeq
NM_001082260.2). The vectors were added to competent
XL1 blue E. coli (Stratagene), and two independent colonies
of each insert (mutant and wild-type) were selected for
plasmid extraction with the QIAfilter Plasmid Midi Kit
(QIAGEN). The sequences of the two insertswere confirmed
before their transient expression in mammalian cells.
Lipofectamine 2000 (Invitrogen) was used for transfec-
tions in COS7 cells with 2 mg of DNA. Cells were harvested
48 hr after transfection and homogenized in TRIzol
Reagent (Invitrogen) for RNA isolation. The cDNA was
synthesized with the QuantiTect Reverse Transcription
Kit (QIAGEN). GAPDH was used as a control for cDNA
quantity. The RT-PCR of the studied variant was done
with beta-globin primers: 50 primer 50-TCTGAGTCACCTG
GACAACCT-30 and 30 primer 50-ATCTCAGTGGTATTTGT
GAGC-30. PCR products were loaded on an agarose gel;
bands were extracted and purified with the QIAquick Gel
Extraction Kit (QIAGEN). The purified products were sent
for sequencing, and the sequences were analyzed with
SeqManII (DNASTAR).
Sequencing revealed that the wild-type allele (allele T)
yielded a ~300 bp product that was predicted to arise
from normal splicing. Also seen with the wild-type allele
was a second product of ~400 bp. By opposition, the corre-
sponding RT-PCR reactions prepared with the mutantetics 91, 548–552, September 7, 2012 549
Table 1. Genetic Screening Results of the Families and Probands
Family Name
Mutation Carrier Mutation Noncarrier
TotalAffected Unaffected Unknown Affected Unaffected Married In Unknown
FPSAT6 6 0 3 0 1 0 0 10
Fam27 13 0 2 0 4 3 0 22
Fam71 10 0 0 0 13 1 0 24
Fam13 21 0 3 0 17 9 1 51
Probands 3 0 0 0 0 0 0 3
Total 53 0 8 0 35 13 1 110allele cDNA (allele G at the variant position) only showed
the ~400 bp product (Figure 2A). This observation fully
supports our original prediction about the impact of the
c.340þ2T>G mutation on normal splicing. The ~400 bp
fragment in cells expressing the wild-type minigene is
most likely the consequence of the minigene system,
which would have forced the use of any possible splicing
sequence present. Moreover, the usual splice site of
VAMP1 in intron 4 has been shown to be a weak donor
site.9 The sequencing of the ~400 bp band revealed that
another splicing donor site was used (Figure 2B). This
downstream VAMP1A splice site is 99 bp after the variant
position, and at the protein level, the resulting amino
acid sequence due to aberrant splicing would be similar
to that of VAMP1D because there is an in-frame stop codon
before the splicing site. Furthermore, the mutant cDNA
would produce a VAMP1D protein containing a missense
alteration: p.Ser114Arg (Figure 1C).
The neuronal VAMPs are involved in the synaptic vesicle
cycle at the presynaptic nerve terminal. They are anchored
in the vesicle membrane by their C-terminal domain and
interact with synaptophysin prior to docking of the
vesicle. When docking happens, they bind the complex
SNAP-25 and syntaxin to form the synaptic core complex,
starting the cascade of protein-protein interactions leading
to neurotransmitter exocytosis. Several clostridial toxins,550 The American Journal of Human Genetics 91, 548–552, Septembnamely tetanus toxin and botulinum toxins B, D, F,
and G, are known to cleave VAMP proteins. These toxins
block the release of neurotransmitters either in the CNS
or in the peripheral nervous system, arguing that VAMPs
are essential for exocytosis.10,11
VAMP proteins have been extensively studied with
rat (Rattus norvegicus) models, although the electric ray
(Torpedo californica) was the first organism in which
VAMP1 (synaptobrevin 1 or SYB_TORCA) was reported.12,13
The first discovered synaptobrevin protein (Vamp1) was
reported to be expressed in the nervous system and endo-
crine cells, and it was also found that the rat genome
contains two different genes encoding two similar
proteins, Vamp1 and Vamp2;12–14 both are expressed in
the nervous system but at distinct localizations. Vamp1 is
expressed in the rat cerebellum, a structure known to be
involved in ataxias in humans.15 The protein is also
present in the rat brainstem and spinal cord, more specifi-
cally in the nuclei controlling eye movements, tongue
movements, swallowing, and limb movements.16–18 All
these CNS structures are consistent with some of the
SPAX1 symptoms.
A few years after the original report describing Vamp1,
the use of an alternative splice site was shown to underlie a
distinct isoform that was henceforth named Vamp1b. This
second isoform is exclusively expressed in nonneuronal ratFigure 2. Testing Splicingwith RNA from
Transfected COS7 Cells
(A) Agarose-gel result of RT-PCR on RNA
extracted from COS7 cells transfected
with a VAMP1minigene. The allele present
in the insert is indicated above the corre-
sponding lane.
(B) Representation of the plasmid portion
relevant for RT-PCR. The beta-globin exons
are in gray, the splicing events are repre-
sented by blue lines, and the variant posi-
tion is indicated by the red dashed line.
The insert, in red, has introns (lines) and
an exon (wider box). The medium-sized
box represents the nucleotides added by
the abnormal splicing. The presented
sequence represents the sequence of the
insert; the mutated T is highlighted in
red, and the alternatively used donor site
is highlighted in yellow.
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tissues, such as the kidneys, spleen, liver, parotid, and
pancreas.9 The isoform Vamp1b region that diverged
from the original isoform, now termed Vamp1a, was in
the C-terminal of the protein. The authors suggested that
the splicing was tissue specific and that the normal splicing
was disrupted as a result of a weak 50 donor splicing motif.9
In this last isoform, exon 4 continues, leading to a product
~400 bp larger. Moreover, 3 years ago, another group found
a Vamp1 isoform, termed Vamp1nv, specific to the rat’s
cochlear nucleus; again, it diverges only in the C-terminal
of the protein.19
In 1999, a report by Berglund20 and colleagues identified
six distinct VAMP1 isoforms, but only three of these are
presently listed in the human genome (GRCh37/hg19).
The VAMP1A (RefSeq NM_014231.3) isoform is mostly ex-
pressed in the nervous system,20 and the protein sequence
encoded by this isoform is similar to the electric ray
SYB_TORCA and rat Vamp1a orthologs. VAMP1B (RefSeq
NM_016830.2) is an isoformwith a broad tissue expression
(e.g., T cells, neutrophils, fibroblasts, liver cells, endothelial
cells, and more) but is noticeably not expressed in the
human brain.17 In fact, the expression of VAMP1A and
VAMP1B is believed to be, to a certain extent, mutually
exclusive.17 In humans, the VAMP1A and VAMP1B iso-
forms encompass the same first four exons but the
following and last exon, which carries a mitochondrial
targeting signal in VAMP1B, is distinct between these two
isoforms.21,22 The thirdVAMP1 isoform isVAMP1D (RefSeq
NM_199245.1), which is almost identical to the rat
Vamp1b and is therefore probably not expressed in the
nervous system. In this third isoform, the translation of
the fourth exon continues until it reaches a stop codon
12 nucleotides downstream (c.354). The normal donor
site located at the end of exon 4 (c.340þ2), which is critical
for the differential isoform splicing events, is the donor site
mutated in the SPAX1 patients. Therefore, the mRNA
normal splicing of both VAMP1A and VAMP1B is likely to
be affected.
Using RNA-Seq data from Illumina’s Human BodyMap
2.0 (see Web Resources), we were able to confirm the
presence of VAMP1A mRNA in the Brain and Brain_R
libraries by using the Scripture and Cufflinks programs.
A VAMP1B mRNA sequence was shown only once in the
Brain library. As for VAMP1D, it never appeared to be
expressed in the brain. Consequently, we predict that
the mutation in patients leads to alternative splicing
with the formation of an abnormal inactive isoform in
neurons and subsequently results in haploinsufficiency.
Therefore, there would be less neurotransmitter exocy-
tosis in specific regions of the brain, causing the symp-
toms of SPAX1. Without autopsy material, it is not
possible to determine whether the p.Ser114Arg VAMP1D
is aberrantly expressed in the brain and thereby possibly
leads to neuronal damage. However, given that this
isoform is normally expressed only in nonneuronal
tissues, it seems unlikely that it will lead to the HSA
phenotype.The AmericanThere is a spontaneous Vamp1-null mouse model called
lethal wasting (lew), in which a mutation causes the trun-
cation of half of the protein; hence, no Vamp1 is produced.
The phenotype in homozygous mice is mostly neurolog-
ical defects, and the animals die at postnatal day 15.23 In
the mouse, Vamp1 appears to encode a protein that is
essential for the function of neuromuscular junction,
specifically for Ca2þ sensitivity.24 Other synapses were
not studied, but one could speculate that the role of
VAMP1 in the CNS is likely to be similar. Vamp1-heterozy-
gous mice appear normal; however, a detailed assessment
of the impact on the brain was not done (W. Lin, personal
communication).
We have identified a VAMP1 variant that segregates in
four HSA-affected families from Newfoundland and that
is present in three additional probands. This variant is
absent from 169 Newfoundland population controls (the
affected families are from Newfoundland), as well as every
other population looked at. Using a minigene, we estab-
lished that the variant has an effect on the splicing of
the RNA primarily affecting a neuron-specific isoform.
We suspect that the amount of this neuron-specific
VAMP1 isoform is reduced by half and that this leads to
the neurological deficiencies observed clinically. Because
this variant is the only rare and heterozygous one found
in the 1.9 Mb disease-haplotype region and because it is
putatively damaging, the odds of its being disease causing
are high. Nonetheless, experiments with patients’ tissues
or, perhaps, animal models will be needed for establishing
the disease mechanism and for further validating this
variant as the real causative one.
Patients with HSA, HSP, or ataxia and who have ancestral
links in Newfoundland should be tested for mutations in
this gene. Indeed, VAMP1 is part of the membrane-
trafficking and axonal transport family of proteins,10 and
proteins with these roles have been linked to both domi-
nant ataxias25 and HSPs,26 which encompass the HSA
phenotype. Thus, beyond the similarity of phenotypes,
the roles of VAMP1 make it a relevant candidate for all
three families of disorders. It also remains to be determined
whether mutations in this genemight be found in patients
outside of this Newfoundland founder effect.Supplemental Data
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